2009•Zhongguo yaofangRequires access

Cost-Minimization Analysis of Cefoperazone/Sulbactam Sodium vs. Moxifloxacin in the Treatment of Community Acquired Pneumonia

Zhenghua Jiang

Abstract

OBJECTIVE:To evaluate the economic effects of cefoperazone/sulbactam sodium and moxifloxacin for community acquired pneumonia.METHODS:92 patients with community acquired pneumonia were randomly assigned to receive cefoperazone/sulbactam sodium for injection(Group A) or moxifloxacin injection(Group B),respectively.In both groups the observation of curative effects and safety and the pharmacoeconomic analysis were conducted.RESULTS:The effective rates of two groups were 86.00% and 92.86%(P0.05),respectively.The average cost was 1 314.8 yuan in Group A versus 3 306.5 yuan in Group B(P0.05).CONCLUSION:The therapy of Group A is more benefit between two groups.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Moxifloxacin, Cefoperazone, Medicine, Community-acquired pneumonia, Cost-minimization analysis, Pneumonia, Sulbactam, Internal medicine